Recent progress in developing of thrombolytic agents for ischemic stroke.

Yanyan XU; Shanli Chen; Dan Chen; Shuangzhou Peng; Yuan Cheng; Jinyu LI; Yongkun LI; Longguang Jiang; Cai Yuan; Mingdong Huang

Return

Recent progress in developing of thrombolytic agents for ischemic stroke.

Author: Yanyan XU ¹ ; Shanli CHEN ² ; Dan CHEN ² ; Shuangzhou PENG ³ ; Yuan CHENG ² ; Jinyu LI ² ; Yongkun LI ⁴ ; Longguang JIANG ² ; Cai YUAN ¹ ; Mingdong HUANG ²
Author Information

1. College of Biological Science and Engineering, Fuzhou University, Fuzhou 350116, Fujian, China.
2. College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
3. College of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, Fujian, China.
4. Department of Neurology, Fujian Provincial Hospital, Provincial Clinical Department of Fujian Medical University, Fuzhou 350001, Fujian, China.
Publication Type:Review
Keywords: ischemic stroke; thrombolysis; tissue plasminogen activator
MeSH: Brain Ischemia/drug therapy*; Fibrinolytic Agents/therapeutic use*; Humans; Research/trends*; Stroke/drug therapy*; Thrombolytic Therapy/trends*; Tissue Plasminogen Activator/therapeutic use*
From: Chinese Journal of Biotechnology 2020;36(10):2029-2039
CountryChina
Language:Chinese
Abstract: Ischemic stroke is a major health crisis causing high mortality and morbidity. The key treatment relies on the rapid intervention to dissolve thrombus, to reduce bleeding side effect and re-canalize clotted blood vessels using clot lysis drugs. Tissue plasminogen activator (tPA) is the only FDA-approved drug for ischemic stroke, but it has many limitations in clinical use. In recent years, the development of thrombolytic drugs and treatment strategies based on tPA has been progressed rapidly. Here we review the recent progress in this field, including the contributions from us and others, to promote the future development of novel thrombolytic drugs.